TY - JOUR
T1 - Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses
AU - Azzam, Diana J.
AU - Zhao, Dekuang
AU - Sun, Jun
AU - Minn, Andy J.
AU - Ranganathan, Prathibha
AU - Drews-Elger, Katherine
AU - Han, Xiaoqing
AU - Picon-Ruiz, Manuel
AU - Gilbert, Candace A.
AU - Wander, Seth A.
AU - Capobianco, Anthony J.
AU - El-Ashry, Dorraya
AU - Slingerland, Joyce M.
PY - 2013/10
Y1 - 2013/10
N2 - Increasing evidence suggests that stem-like cells mediate cancer therapy resistance and metastasis. Breast tumour-initiating stem cells (T-ISC) are known to be enriched in CD44+CD24neg/low cells. Here, we identify two T-ISC subsets within this population in triple negative breast cancer (TNBC) lines and dissociated primary breast cancer cultures: CD44+CD24low+ subpopulation generates CD44+CD24neg progeny with reduced sphere formation and tumourigenicity. CD44+CD24low+ populations contain subsets of ALDH1+ and ESA+ cells, yield more frequent spheres and/or T-ISC in limiting dilution assays, preferentially express metastatic gene signatures and show greater motility, invasion and, in the MDA-MB-231 model, metastatic potential. CD44+CD24low+ but not CD44+CD24neg express activated Notch1 intracellular domain (N1-ICD) and Notch target genes. We show N1-ICD transactivates SOX2 to increase sphere formation, ALDH1+ and CD44+CD24low+cells. Gamma secretase inhibitors (GSI) reduced sphere formation and xenograft growth from CD44+CD24low+ cells, but CD44+CD24neg were resistant. While GSI hold promise for targeting T-ISC, stem cell heterogeneity as observed herein, could limit GSI efficacy. These data suggest a breast T-ISC hierarchy in which distinct pathways drive developmentally related subpopulations with different anti-cancer drug responsiveness.
AB - Increasing evidence suggests that stem-like cells mediate cancer therapy resistance and metastasis. Breast tumour-initiating stem cells (T-ISC) are known to be enriched in CD44+CD24neg/low cells. Here, we identify two T-ISC subsets within this population in triple negative breast cancer (TNBC) lines and dissociated primary breast cancer cultures: CD44+CD24low+ subpopulation generates CD44+CD24neg progeny with reduced sphere formation and tumourigenicity. CD44+CD24low+ populations contain subsets of ALDH1+ and ESA+ cells, yield more frequent spheres and/or T-ISC in limiting dilution assays, preferentially express metastatic gene signatures and show greater motility, invasion and, in the MDA-MB-231 model, metastatic potential. CD44+CD24low+ but not CD44+CD24neg express activated Notch1 intracellular domain (N1-ICD) and Notch target genes. We show N1-ICD transactivates SOX2 to increase sphere formation, ALDH1+ and CD44+CD24low+cells. Gamma secretase inhibitors (GSI) reduced sphere formation and xenograft growth from CD44+CD24low+ cells, but CD44+CD24neg were resistant. While GSI hold promise for targeting T-ISC, stem cell heterogeneity as observed herein, could limit GSI efficacy. These data suggest a breast T-ISC hierarchy in which distinct pathways drive developmentally related subpopulations with different anti-cancer drug responsiveness.
KW - Breast cancer stem cells
KW - GSI
KW - Metastasis
KW - Notch1
KW - Sox2
UR - http://www.scopus.com/inward/record.url?scp=84884969557&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884969557&partnerID=8YFLogxK
U2 - 10.1002/emmm.201302558
DO - 10.1002/emmm.201302558
M3 - Article
C2 - 23982961
AN - SCOPUS:84884969557
SN - 1757-4676
VL - 5
SP - 1502
EP - 1522
JO - EMBO Molecular Medicine
JF - EMBO Molecular Medicine
IS - 10
ER -